• 1
    Stegall M, Gloor J, Winters J, Moore S, DeGoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific antibody. Am J Transplant 2006; 6: 346351.
  • 2
    Jordan SC, Vo AA, Peng A, Toyoda M, Tyan D. Intravenous gammaglobulin (IVIG): A novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 2006; 6: 459466.
  • 3
    Jordan SC, Tyan D, Stablein D et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15: 32563262.
  • 4
    Toyoda M, Petrosyan A, Hilo L et al. IVIG modulation of anti-HLA class 1 and class 2 antibody production in highly-sensitized patients is selective and not random: An analysis of the IGO2 study. Am J Transplant 2004; 8: 583. (Abstract)
  • 5
    Jordan SC, Vo A, Bunnapradist S et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003; 76: 631636.